Diasorin, revenues hold at 1.19 billion (+1%) but profit drops to 150 million

Diasorin closed 2025 with slightly higher revenues and Ebitda, in line with forecasts for 2025. Revenues stood at 1,195 million: the increase is 4% at constant exchange rates compared to 2024 and 1% at current exchange rates (due to a negative exchange rate effect of 34 million), +5% excluding Covid. Adjusted EBITDA was EUR 394 million, +4% at constant exchange rates compared to 2024, in line at current exchange rates (with a negative exchange rate effect of EUR 15 million), with a margin of 33% as a percentage of revenue, both at current and constant exchange rates. Net profit was EUR 150 million, down 20% at current exchange rates, while adjusted net profit was EUR 223 million (19% as a percentage of revenue), down EUR 13 million (-6%) from 2024, as a result of 'an unfavourable exchange rate effect, higher adjusted net financial expenses and higher taxes for the year'.

The Board of Directors proposed the payment of an ordinary dividend of EUR 1.30 per share, an increase of 8.3% compared to 2024. For 2026, the company sees, at constant exchange rates, revenues growing between +5% and +6% and an adjusted Ebitda margin of 32%-33%. The guidance indicated by the company, it is specified in a note, "does not take into account the potential negative impact of the current military conflict in the Middle East, which could be reflected on the group's sales in the region" and "excludes the possible indirect effects of the conflict itself, including greater logistical and distribution difficulties, also towards the Asia-Pacific area, as well as potential inflationary effects on costs and supply chain related to the current geopolitical context". As of today's date - the note explained, however - it is not possible to make forecasts, so Diasorin "will communicate any updates to the market as soon as the context allows for a more accurate assessment".

In the fourth quarter of 2025, Diasorin launched a project aimed at reorganising operations at its Chinese subsidiary, in continuity with the path already taken through similar initiatives and as part of its strategy to optimise production sites globally, aimed at strengthening competitiveness in the long term. The decision stems from the sustainability analysis of the Chinese plant, conducted in light of the new macroeconomic conditions and the introduction of the Volume-Based Procurement (VBP) regulation. The operation, scheduled for completion by the end of 2026, 'will be implemented in accordance with existing contractual agreements' and will generate operating synergies and annual savings estimated at around €6 million, with a monetary payback of less than one year.